We performed an open-label single-institution phase II trial of mirtazapine (15-30 mg by mouth [po] every day [qd]), a tetracyclic antidepressant that may lead to weight gain, for 8 weeks in nondepressed patients with cancer-related cachexia/anorexia (CRCA). The primary end point was the proportion of patients who gained ≥1 kg at week 4. Secondary end points were quality of life and appetite. From June 2006 to July 2007, 17 of 58 eligible patients were enrolled. On intention-to-treat analysis at week 4, 4 of 17 patients (24%) gained 1 kg or more, 1 patient maintained weight (gain of 400 g) and 2 patients lost weight (800 g and 1.2 kg); 24% and 6% improved appetite and health-related quality of life (HQOL), respectively. Mirtazapine is a promising agent for the treatment of CRCA.
Walsh D., Donnelly S., Rybicki L.The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer. 2000;8(3):175-179.
2.
Dewys WD, Begg C., Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69(4):491-497.
3.
Davis MP, Dreicer R., Walsh D., Lagman R., LeGrand SBAppetite and cancer-associated anorexia: a review. J Clin Oncol. 2004; 22(8):1510-1517.
4.
Argiles JM, Moore-Carrasco R., Fuster G., Busquets S., Lopez-Soriano FJCancer cachexia: the molecular mechanisms. Int J Biochem Cell Biol. 2003;35(4): 405-409.
5.
Goldberg RM, Loprinzi CL, Mailliard JA, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol. 1995;13(11):2856-2859.
6.
Bruera E., Neumann CM, Pituskin E., Calder K., Ball G., Hanson J.Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol. 1999;10(7):857-859.
7.
Sakamoto M., Mikasa K., Hamada K., et al. [Efficacy of clarithromycin on cancer cachexia in patients with primary non-small cell lung cancer]. Jpn J Antibiot. 1997;50(suppl A): 38-41.
8.
Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. 1999; 17(10):3299-3306.
9.
Jatoi A., Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study . J Clin Oncol. 2002;20(2): 567-573.
10.
Jatoi A., Rowland K., Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort . J Clin Oncol. 2004;22(12):2469-2476.
11.
Loprinzi CL , Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst. 1990;82(13): 1127-1132.
12.
Tchekmedyian NS, Hickman M., Siau J., Greco A., Aisner J.Treatment of cancer anorexia with megestrol acetate: impact on quality of life. Oncology ( Williston Park). 1990;4(5):185-192; discussion 194.
13.
Westman G., Bergman B., Albertsson M., et al. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. Eur J Cancer. 1999;35(4):586-595.
14.
Beller E., Tattersall M., Lumley T., et al. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group. Ann Oncol. 1997;8(3): 277-283.
15.
Barber MD, Fearon KC, Delmore G., Loprinzi CLShould cancer patients with incurable disease receive parenteral or enteral nutritional support? Eur J Cancer. 1998;34(3):279-285.
16.
Nutt DJTolerability and safety aspects of mirtazapine. Hum Psychopharmacol . 2002;17(suppl 1):S37-S41.
17.
Anttila SA, Leinonen EVA review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249-264.
18.
Vanina Y., Podolskaya A., Sedky K., et al. Body weight changes associated with psychopharmacology. Psychiatr Serv. 2002; 53(7):842-847.
19.
Richelson E.Pharmacology of antidepressants-characteristics of the ideal drug. Mayo Clin Proc. 1994;69(11):1069-1081.
20.
Kast REAnti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels. Gen Hosp Psychiatry. 2003;25(6):495-496.
21.
Kraus T., Haack M., Schuld A., Hinze-Selch D., Koethe D., Pollmacher T.Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry . 2002;35(6):220-225.
22.
Davis MP, Khawam E., Pozuelo L., Lagman R.Management of symptoms associated with advanced cancer: olanzapine and mirtazapine . A World Health Organization project. Expert Rev Anticancer Ther. 2002;2(4): 365-376.
Theobald DE , Kirsh KL, Holtsclaw E., Donaghy K., Passik SDAn open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms . J Pain Symptom Manage. 2002; 23(5):442-447.
25.
Zimmermann C., Seccareccia D., Clarke A., Warr D., Rodin G.Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital. Support Care Cancer. 2006;14(10):982-987.
26.
Bruera E., Kuehn N., Miller MJ, Selmser P., Macmillan K.The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6-9.
27.
Beck AT, Steer RA, Ball R., Ranieri W.Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients . J Pers Assess. 1996;67(3):588-597.
28.
Chochinov HM , Wilson KG, Enns M., Lander S.‘‘Are you depressed?’’ Screening for depression in the terminally ill. Am J Psychiatry . 1997;154(5):674-676.
29.
Endicott J. , Spitzer RLA diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry. 1978;35(7):837-844.
30.
Friedman LM, Furberg CD, DeMets DLFundamentals of Clinical Trials. 3rd ed. New York: Springer; 1998.
31.
Cella DFFACIT Manual: Manual of the Functional Assessment of Chronic Illness (FACIT scales). Center on Outcomes Research and Education (CORE), Evanston: Northwestern Healthcare and Northwestern University. 1997.
32.
Osoba D., Rodrigues G., Myles J., Zee B., Pater J.Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139-144.
33.
Omlin AG, Strasser F.Secondary causes of cancer-related anorexia: recognition in daily practice by a novel checklist, a pilot study. J Clin Oncol ASCO Annual Meeting Proceedings Part I.2007;25(18S):9058.
34.
Strasser F.The silent symptom early satiety: a forerunner of distinct phenotypes of anorexia/cachexia syndromes. Support Care Cancer. 2006;14(7):689-692.
35.
Strasser F. , Luftner D., Possinger K., et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group . J Clin Oncol. 2006;24(21): 3394-3400.
36.
Ruiz-Garcia V., Juan O., Perez Hoyos S., et al. [Megestrol acetate: a systematic review usefulness about the weight gain in neoplastic patients with cachexia]. Med Clin (Barc). 2002;119(5): 166-170.
37.
Yavuzsen T. , Davis MP, Walsh D., LeGrand S., Lagman R.Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol. 2005 ; 23(33):8500-8511.
38.
Steinhauser KE, Clipp EC, Hays JC, et al. Identifying, recruiting, and retaining seriously-ill patients and their caregivers in longitudinal research. Palliat Med. 2006;20(8):745-754.
